Ghita Meknassi Salime

Ghita Meknassi Salime

Auto-generated profile, based on publicly available information

Ghita Meknassi Salime

Department of Galenic Pharmacy and Pharmacotehnics, Faculty of Medicine and Pharmacy, Mohammed V. University, Rabat, Morocco

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Hospital Pharmacy
Verified
Journal Article
Closed access
GSGhita Meknassi Salime
Ghita Meknassi Salime
NBNihal Bhirich
Nihal Bhirich
ACAli Cherif Chefchaouni
Ali Cherif Chefchaouni
OEOmar omar Elhamdaoui
Omar omar Elhamdaoui
SBSoumaya El Baraka
Soumaya El Baraka
YEYassir Elalaoui
Yassir Elalaoui
Medication management in hospitals is a complex process that encompasses every step from prescription to administration, involving multiple healthcare professionals. This process is prone to various errors that can compromise patient safety and generate significant human and financial costs. Automation in hospital pharmacies represents a major advancement, enhancing patient safety, optimizing professional practices, and reducing hospital expenses. This study aims to analyze the different types of automation systems used in hospital pharmacies, assess the impact of automation, and explore its benefits as well as the challenges and limitations associated with its implementation. A literature search was conducted using the ScienceDirect, PubMed, and Scopus databases, covering the period from 1992 to 2024. A total of 129 relevant articles related to the automation of medication preparation and distribution, as well as its challenges and perspectives were included in this study. Automated technologies significantly contribute to reducing medication errors, strengthening traceability, optimizing inventory management, and alleviating the workload of healthcare professionals. However, challenges persist, particularly in terms of costs, integration with existing processes, and staff training. The use of artificial intelligence offers promising prospects for improving the accuracy and operational efficiency of automation systems.

15 July 2025 in Vegetos
Verified
Journal Article
Closed access
PDF file
ABAbdelhafid Benomar
Abdelhafid Benomar
GSGhita Meknassi Salime
Ghita Meknassi Salime
MMMeryem Mabrouki
Meryem Mabrouki
MFMohamed Fekrouni
Mohamed Fekrouni
RCRajae Chahboune
Rajae Chahboune
MBMustapha Bouatia
Mustapha Bouatia

31 October 2024 in Annales Pharmaceutiques Françaises
Verified
Journal Article
Closed access
GSGhita Meknassi Salime
Ghita Meknassi Salime
ACAli Cherif Chefchaouni
Ali Cherif Chefchaouni
OEOmar ElHamdaoui
Omar ElHamdaoui
YEYassir Elalaoui
Yassir Elalaoui

30 June 2025 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
GSGhita Meknassi Salime
Ghita Meknassi Salime
NBNihal Bhirich
Nihal Bhirich
AAAbdelghani Asraoui
Abdelghani Asraoui
MKMoulay El Hassan El Karimi
Moulay El Hassan El Karimi
YRYounes Rahali
Younes Rahali
HSHouda Sefiani
Houda Sefiani
Background: Since 2016, Moroccan pharmaceutical companies have been required to report adverse effects linked to their medicines. Initially, reports were submitted using the CIOMS form, sent by normal mail to le Centre Antipoison et de Pharmacovigilance du Maroc, then using XML files in ICH E2B format, sent electronically. In 2021, a "vigiflow e-reporting for industry" standardized online reporting system was implemented. The primary objective of this study was to evaluate the pharmaceutical companies'; use of electronic reporting. Secondarily, the study aimed to assess the quality of adverse drug reaction reports by comparing completeness scores across the three reporting means. Methods: All individual case safety reports sent by pharmaceutical companies from January 1, 2019, to December 31, 2023, were extracted from Vigibase®. A quantitative and qualitative analysis was conducted, and a statistical comparison of data was performed using p-values. VigiGrade completeness score was calculated for a sample size selected. Results: The highest number of reports were from E-reporting (50%), followed by CIOMS (29%) and E2B (21%). Between 2019 and 2021, CIOMS and E2B notifications decreased along with reporting laboratories. However, after 2021, electronic reporting increased steadily alongside reporting companies. Comparing vigiGrade completeness score across reporting means revealed no statistically significant differences (p = 0.094 > 0.05). Conclusion: Electronic reporting shows quantitative effectiveness and consistent quality. Its adoption remains limited and requires continuous strengthening, particularly through increased awareness among pharmaceutical companies

1 October 2025 in Current Nanomedicine
Verified
Journal Article
Closed access
PDF file
NBNihal Bhirich
Nihal Bhirich
GMGhita Salime Meknassi
Ghita Salime Meknassi
MYMohammed Yafout
Mohammed Yafout
YRYounes Rahali
Younes Rahali
The complexity of the management of cancerous conditions requires innovative strategies, including the pharmacotechnical optimization of treatments. The improvement of galenic forms, or more generally of drug delivery, represents a rapidly developing area of research, particularly in oncology, in order to remedy side effects and drug resistance remains a worrying problem. Carbon nanotubes CNTs consist of thin sheets of benzene carbons coiled into a seamless tubular structure. These CNTs have remarkable size and surface properties that make them the ideal vehicle for targeted and selective drug delivery. Different in vitro and in vivo experiments have proven that these particles can be easily modified in such a way that the chemical drug can be delivered directly to the tumor site. Additionally, different types of ligands can be loaded on the surface of CNTs to improve selectivity or modulate drug release. On the other hand, advances in carbon nanotubes could well lead to a more effective understanding of biological and physicochemical processes. This will make it possible to find compounds more compatible with carbon nanotube technology and facilitate their use.